Leading European experts recommend innovative treatment for hypertension; MPN aims to recruit 1st patient in clinical trial
From middle age on, up to 60% of people have some problems with high blood pressure (BP). Cardiovascular Research Institute Dublin at Mater Private Network has announced details of a new clinical trial evaluating an innovative treatment for patients with high blood pressure.
This announcement comes ahead of a special GP webinar hosted by the leading private hospital group entitled “Hypertension & Blood Pressure – A Multi-Disciplinary Team (MDT) Approach to Patient Management,” which will take place on Monday 18th October. Contact email@example.com for registration details.
Enrolling patients in Ireland from 18 – 80 years old who have been unsuccessful in managing their condition through drug therapies and life-style changes, the advanced TARGET BP 1 clinical trial at Mater Private Network is intended to evaluate the safety and efficacy of the Peregrine System™ Kit Procedure. Reducing the effects of hypertension through alcohol-mediated denervation of the respective renal arteries, this catheter-based trial procedure has been designed to calm the nerves surrounding the Kidney which can contribute to raising blood pressure.
Expanding on the findings of earlier Renal Denervation trials, Director of Cardiology at the Mater Private Network, Chair of Cardiovascular Research at the RCSI University of Medicine and Health Sciences and TARGET BP 1principal investigator, Professor Robert Byrne said: “Hypertension, if untreated, can lead to stroke, heart failure, and kidney disease, among many other complications.”
In spite of their best efforts a proportion of patient remain unable to adequately manage their condition. There is renewed hope that these patients can be successfully treated with renal ablation, based on a series of recent positive studies, which has led experts in Europe to recommend this treatment in a position paper published in a leading journal, on 1 September 2021.
He also said; “While standard treatments can be very effective, this trial could have long-term benefits for a number of patients across Ireland who remain unable to adequately control their condition with standard therapies.”
The Peregrine System Kit Procedure is performed through a single, small incision in the groin. A thin, flexible catheter is then guided to the artery supplying the kidney. Once positioned, the Peregrine System Catheter delivers a small amount of dehydrated alcohol to the region just outside the artery aiming to deactivate a network of nerves, which drive high BP in certain patients. After the arteries to both kidneys are treated, the Peregrine Catheter is removed, and the incision is closed.
Patients who are interested in taking part in the clinical trial at Mater Private Network should contact Hannah Wilson, Clinical Research Nurse via email at firstname.lastname@example.org. Further information can be found at http://targetbp-uk.com/.
*Both public and private patients are eligible.